Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

Oxaliplatin 10Fluorouracil 7Leucovorin 6Gemcitabine 6Docetaxel 6Capecitabine 6Paclitaxel 5Cisplatin 5zolbetuximab 4Ramucirumab 3Pemetrexed 3Drug Therapy 3Carboplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3regorafenib 2pembrolizumab 2Vinorelbine 2Surgical Procedures, Operative 2Radiotherapy 2Nivolumab 2Neoadjuvant Therapy 2Cyclophosphamide 2Chemoradiotherapy 2Bevacizumab 2Afatinib 2vandetanib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma × linifanib × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡